Mixture of HMOs for treating wheat sensitivity
View Patent ↗The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.
1. A method of treating non-coeliac wheat and/or gluten sensitivity in a human, comprising administering, to a human in need thereof, one or more human milk oligosaccharides (HMOs) selected from the group consisting of 2′-FL, LNnT, LNT and DFL; or a combination thereof.
2. The method according to claim 1 , wherein the one or more HMOs are administered in a synthetic composition.
3. The method according to claim 2 , wherein the synthetic composition comprises an amount of 1 g to 15 g of the at least one HMO.
4. The method according to claim 1 , wherein the one or more HMOs comprise 2′-FL.
5. The method according to claim 1 , wherein the one or more HMOs comprise LNnT.
6. The method according to claim 1 , wherein the one or more HMOs comprise LNT.
7. The method according to claim 2 , wherein the synthetic composition comprises at least one of 2′-FL and DFL, and at least one of LNnT and LNT.
8. The method according to claim 7 , wherein the synthetic composition comprises 2′-FL and LNnT.
9. The method according to claim 1 , in which the human is administered an amount of 3 g to 15 g per day of the one or more HMOs.
10. The method according to claim 1 , wherein the one or more HMOs is administered to the human for at least 7 consecutive days.
11. The method according to claim 1 , in which the patient is administered the one or more HMOs while consuming gluten containing cereals.
12. The method according to claim 1 , the method comprises administering the one or more HMOs at a first dose in a first phase to treat the non-coeliac wheat and/or gluten sensitivity and administering the one or more HMOs at a second dose in a second phase, wherein the one or more HMOs in the first phase are the same as the one or more HMOs in the second phase.
13. The method according to claim 12 , in which the human is administered a higher dose of the one or more HMOs during the first phase followed by a lower dose of the one or more HMOs during the second phase.
14. The method according to claim 13 , in which the higher dose is about 3 g to about 15 g per day and the lower dose is about 2 g to about 7.5 g per day.
15. The method according to claim 12 , wherein the duration of the first phase is at least consecutive 7 days, and the duration of the second phase is at least four consecutive weeks.
16. The method according to claim 1 , in which the human is administered an amount of about 4 g to about 7.5 g per day of the HMO.
17. The method according to claim 1 , wherein the one or more HMOs comprise DFL.